60.13 USD
+2.32 (+4.01%)
Last: Feb 10, 2026, 02:39 PM
BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on BMRN. These ratings could make BMRN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
- BMRN had positive earnings in the past year.
- In the past year BMRN had a positive cash flow from operations.
- Of the past 5 years BMRN 4 years were profitable.
- In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
- BMRN has a better Return On Assets (6.83%) than 92.54% of its industry peers.
- BMRN has a better Return On Equity (8.59%) than 91.97% of its industry peers.
- BMRN has a Return On Invested Capital of 7.69%. This is amongst the best in the industry. BMRN outperforms 93.88% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 18.12%.
- The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of BMRN (16.82%) is better than 92.54% of its industry peers.
- With an excellent Operating Margin value of 20.21%, BMRN belongs to the best of the industry, outperforming 94.46% of the companies in the same industry.
- BMRN's Gross Margin of 81.32% is amongst the best of the industry. BMRN outperforms 85.28% of its industry peers.
- In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMRN is destroying value.
- BMRN has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, BMRN has more shares outstanding
- The debt/assets ratio for BMRN has been reduced compared to a year ago.
2.2 Solvency
- BMRN has an Altman-Z score of 5.47. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
- BMRN has a Altman-Z score of 5.47. This is in the better half of the industry: BMRN outperforms 74.00% of its industry peers.
- BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
- BMRN has a better Debt to FCF ratio (0.72) than 94.46% of its industry peers.
- A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
- BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 62.33% of its industry peers.
- Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.47 |
ROIC/WACC0.63
WACC12.12%
2.3 Liquidity
- A Current Ratio of 4.83 indicates that BMRN has no problem at all paying its short term obligations.
- BMRN has a Current ratio (4.83) which is comparable to the rest of the industry.
- A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
- BMRN's Quick ratio of 3.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 60.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 52.00% over the past year.
- Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
- The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
- Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.19% on average per year.
- BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.22% yearly.
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y28.19%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y7.22%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- BMRN is valuated rather expensively with a Price/Earnings ratio of 22.61.
- Based on the Price/Earnings ratio, BMRN is valued cheaper than 94.65% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.06, BMRN is valued at the same level.
- BMRN is valuated correctly with a Price/Forward Earnings ratio of 13.56.
- 97.32% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
- BMRN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.61 | ||
| Fwd PE | 13.56 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaper than 95.41% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 97.32% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.99 | ||
| EV/EBITDA | 14.12 |
4.3 Compensation for Growth
- BMRN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- BMRN has a very decent profitability rating, which may justify a higher PE ratio.
- BMRN's earnings are expected to grow with 34.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.03
PEG (5Y)N/A
EPS Next 2Y41.64%
EPS Next 3Y34.83%
5. Dividend
5.1 Amount
- BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BMRN (2/10/2026, 2:39:50 PM)
60.13
+2.32 (+4.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27 2025-10-27/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners97.82%
Inst Owner Change-2.63%
Ins Owners0.64%
Ins Owner Change-0.95%
Market Cap11.55B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target94.32 (56.86%)
Short Float %3.88%
Short Ratio2.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)2.44%
PT rev (3m)-1.45%
EPS NQ rev (1m)-32.68%
EPS NQ rev (3m)-35.34%
EPS NY rev (1m)-10.07%
EPS NY rev (3m)-11.2%
Revenue NQ rev (1m)0.64%
Revenue NQ rev (3m)0.21%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.61 | ||
| Fwd PE | 13.56 | ||
| P/S | 3.73 | ||
| P/FCF | 13.99 | ||
| P/OCF | 12.64 | ||
| P/B | 1.91 | ||
| P/tB | 2.05 | ||
| EV/EBITDA | 14.12 |
EPS(TTM)2.66
EY4.42%
EPS(NY)4.43
Fwd EY7.37%
FCF(TTM)4.3
FCFY7.15%
OCF(TTM)4.76
OCFY7.91%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)1.03
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.47 |
F-Score8
WACC12.12%
ROIC/WACC0.63
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 22.03% in the next year.